

NOTICE: Oxbryta Discontinued Use Effective Immediately

October 10, 2024

Dear provider,

At the recommendation of AHCCCS, BCBSAZ Health Choice is terming all existing overrides for Oxbryta effective immediately.

On September 26, 2024 Pfizer voluntarily pulled Oxbryta from the market with the following statement:

Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily withdraw OXBRYTA from the market and discontinue distribution and clinical studies while further reviewing the available data and investigating the findings.

In response to the withdrawal of the medication from market due to safety concerns, effective immediately, BCBSAZ Health Choice is terminating all existing prior authorization approvals on file for Oxbryta.

For questions, please contact the plan at 1-800-322-8670.

Thank you for being a valued provider to our BCBSAZ Health Choice members and ensuring the provisions of quality to care.

BCBSAZ Health Choice Arizona

To view this notice for embedded links and content specific to education-related material, please visit us online at <https://www.azblue.com/health-choice-az> under our "For Providers" tab.